

Myelodysplastic Syndrome-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/M7834804AAFMEN.html>

Date: May 2018

Pages: 145

Price: US\$ 3,480.00 (Single User License)

ID: M7834804AAFMEN

Abstracts

Report Summary

Myelodysplastic Syndrome-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Myelodysplastic Syndrome industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Myelodysplastic Syndrome 2013-2017, and development forecast 2018-2023

Main market players of Myelodysplastic Syndrome in Europe, with company and product introduction, position in the Myelodysplastic Syndrome market

Market status and development trend of Myelodysplastic Syndrome by types and applications

Cost and profit status of Myelodysplastic Syndrome, and marketing status

Market growth drivers and challenges

The report segments the Europe Myelodysplastic Syndrome market as:

Europe Myelodysplastic Syndrome Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Myelodysplastic Syndrome Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alkylating Agents

Cytotoxic Antibiotics

Topoisomerase Inhibitors

Others

Europe Myelodysplastic Syndrome Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Europe Myelodysplastic Syndrome Market: Players Segment Analysis (Company and
Product introduction, Myelodysplastic Syndrome Sales Volume, Revenue, Price and
Gross Margin):

Celgene

Novartis

Otsuka

Actinium Pharmaceuticals

Accelaron Pharma

Bellicum Pharmaceuticals

Cornerstone Pharmaceuticals

CTI BioPharma

Onconova Therapeutics

Strategia Therapeutics

KaloBios Pharmaceuticals

Kiadis Pharma

Mirati Therapeutics

Astex

Celator Pharmaceuticals

Eli-lilly

Sunesis Pharmaceuticals

Targazyme
Gamida Cell
GlaxoSmithKline
Sumitomo Dainippon Pharma
TetraLogic Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF MYELOYDYSPLASTIC SYNDROME

- 1.1 Definition of Myelodysplastic Syndrome in This Report
- 1.2 Commercial Types of Myelodysplastic Syndrome
 - 1.2.1 Alkylating Agents
 - 1.2.2 Cytotoxic Antibiotics
 - 1.2.3 Topoisomerase Inhibitors
 - 1.2.4 Others
- 1.3 Downstream Application of Myelodysplastic Syndrome
 - 1.3.1 Hospital
 - 1.3.2 Clinic
- 1.4 Development History of Myelodysplastic Syndrome
- 1.5 Market Status and Trend of Myelodysplastic Syndrome 2013-2023
 - 1.5.1 EMEA Myelodysplastic Syndrome Market Status and Trend 2013-2023
 - 1.5.2 Regional Myelodysplastic Syndrome Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Myelodysplastic Syndrome in EMEA 2013-2017
- 2.2 Consumption Market of Myelodysplastic Syndrome in EMEA by Regions
 - 2.2.1 Consumption Volume of Myelodysplastic Syndrome in EMEA by Regions
 - 2.2.2 Revenue of Myelodysplastic Syndrome in EMEA by Regions
- 2.3 Market Analysis of Myelodysplastic Syndrome in EMEA by Regions
 - 2.3.1 Market Analysis of Myelodysplastic Syndrome in Europe 2013-2017
 - 2.3.2 Market Analysis of Myelodysplastic Syndrome in Middle East 2013-2017
 - 2.3.3 Market Analysis of Myelodysplastic Syndrome in Africa 2013-2017
- 2.4 Market Development Forecast of Myelodysplastic Syndrome in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Myelodysplastic Syndrome in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Myelodysplastic Syndrome by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Myelodysplastic Syndrome in EMEA by Types
 - 3.1.2 Revenue of Myelodysplastic Syndrome in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in Europe
- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Myelodysplastic Syndrome in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Myelodysplastic Syndrome in EMEA by Downstream Industry
- 4.2 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Africa
- 4.3 Market Forecast of Myelodysplastic Syndrome in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MYELODYSPLASTIC SYNDROME

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Myelodysplastic Syndrome Downstream Industry Situation and Trend Overview

CHAPTER 6 MYELODYSPLASTIC SYNDROME MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Myelodysplastic Syndrome in EMEA by Major Players
- 6.2 Revenue of Myelodysplastic Syndrome in EMEA by Major Players
- 6.3 Basic Information of Myelodysplastic Syndrome by Major Players
 - 6.3.1 Headquarters Location and Established Time of Myelodysplastic Syndrome Major Players
 - 6.3.2 Employees and Revenue Level of Myelodysplastic Syndrome Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 MYELODYSPLASTIC SYNDROME MAJOR MANUFACTURERS

INTRODUCTION AND MARKET DATA

7.1 Celgene

7.1.1 Company profile

7.1.2 Representative Myelodysplastic Syndrome Product

7.1.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celgene

7.2 Novartis

7.2.1 Company profile

7.2.2 Representative Myelodysplastic Syndrome Product

7.2.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Novartis

7.3 Otsuka

7.3.1 Company profile

7.3.2 Representative Myelodysplastic Syndrome Product

7.3.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Otsuka

7.4 Actinium Pharmaceuticals

7.4.1 Company profile

7.4.2 Representative Myelodysplastic Syndrome Product

7.4.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Actinium

Pharmaceuticals

7.5 Acceleron Pharma

7.5.1 Company profile

7.5.2 Representative Myelodysplastic Syndrome Product

7.5.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of

Acceleron Pharma

7.6 Bellicum Pharmaceuticals

7.6.1 Company profile

7.6.2 Representative Myelodysplastic Syndrome Product

7.6.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Bellicum

Pharmaceuticals

7.7 Cornerstone Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative Myelodysplastic Syndrome Product

7.7.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of

Cornerstone Pharmaceuticals

7.8 CTI BioPharma

7.8.1 Company profile

7.8.2 Representative Myelodysplastic Syndrome Product

7.8.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of CTI

BioPharma

7.9 Onconova Therapeutics

7.9.1 Company profile

7.9.2 Representative Myelodysplastic Syndrome Product

7.9.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Onconova Therapeutics

7.10 Strategia Therapeutics

7.10.1 Company profile

7.10.2 Representative Myelodysplastic Syndrome Product

7.10.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Strategia Therapeutics

7.11 KaloBios Pharmaceuticals

7.11.1 Company profile

7.11.2 Representative Myelodysplastic Syndrome Product

7.11.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of KaloBios Pharmaceuticals

7.12 Kiadis Pharma

7.12.1 Company profile

7.12.2 Representative Myelodysplastic Syndrome Product

7.12.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Kiadis Pharma

7.13 Mirati Therapeutics

7.13.1 Company profile

7.13.2 Representative Myelodysplastic Syndrome Product

7.13.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Mirati Therapeutics

7.14 Astex

7.14.1 Company profile

7.14.2 Representative Myelodysplastic Syndrome Product

7.14.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Astex

7.15 Celator Pharmaceuticals

7.15.1 Company profile

7.15.2 Representative Myelodysplastic Syndrome Product

7.15.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celator Pharmaceuticals

7.16 Eli-lilly

7.17 Sunesis Pharmaceuticals

7.18 Targazyme

7.19 Gamida Cell

7.20 GlaxoSmithKline

- 7.21 Sumitomo Dainippon Pharma
- 7.22 TetraLogic Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MYELODYSPLASTIC SYNDROME

- 8.1 Industry Chain of Myelodysplastic Syndrome
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MYELODYSPLASTIC SYNDROME

- 9.1 Cost Structure Analysis of Myelodysplastic Syndrome
- 9.2 Raw Materials Cost Analysis of Myelodysplastic Syndrome
- 9.3 Labor Cost Analysis of Myelodysplastic Syndrome
- 9.4 Manufacturing Expenses Analysis of Myelodysplastic Syndrome

CHAPTER 10 MARKETING STATUS ANALYSIS OF MYELODYSPLASTIC SYNDROME

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Myelodysplastic Syndrome-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/M7834804AAFMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M7834804AAFMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970